Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Ernstoff

Showing results (51-60 of 169) with videos related to

Pageof 17
Sort By:
Urology|March 5, 2013
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancerMari Nakabayashi, Wanling Xie, Geoffrey Buckle, et al.
Frontiers in Bioscience (Elite Edition)|May 31, 2011
Novel mobilization strategies to enhance autologous immune effector cells in multiple myelomaLaleh Talebian, Jia Yan Wu, Dawn A Fischer, et al.
Investigational New Drugs|January 15, 2013
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcomaAndrew Poklepovic, Leena E Youssefian, Leena Youseffian, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Journal of Immunological Methods|May 10, 2003
Multiparameter precursor analysis of T-cell responses to antigenNadège Bercovici, Alice L Givan, Mary G Waugh, et al.
Case Reports in Oncology|April 24, 2019
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureNikhil Agrawal, Arjun Khunger, Pankit Vachhani, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2018
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survivalLawrence F Kuklinski, Shaofeng Yan, Zhongze Li, et al.
Clinical Immunology (Orlando, Fla.)|July 20, 2005
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patientsTodd S Crocenzi, Christopher P G Tretter, Thomas Schwaab, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancerLionel D Lewis, Andrew P Beelen, Bernard F Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)Raymond P Perez, Lionel D Lewis, Andrew P Beelen, et al.
Pageof 17

Showing results (51-60 of 169) with videos related to

Sort By:
Pageof 17
Urology|March 5, 2013
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancerMari Nakabayashi, Wanling Xie, Geoffrey Buckle, et al.
Frontiers in Bioscience (Elite Edition)|May 31, 2011
Novel mobilization strategies to enhance autologous immune effector cells in multiple myelomaLaleh Talebian, Jia Yan Wu, Dawn A Fischer, et al.
Investigational New Drugs|January 15, 2013
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcomaAndrew Poklepovic, Leena E Youssefian, Leena Youseffian, et al.
Journal of Chemotherapy (Florence, Italy)|October 8, 2013
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumoursShodeinde A Coker, Uday B Dandamudi, Andrew P Beelen, et al.
Journal of Immunological Methods|May 10, 2003
Multiparameter precursor analysis of T-cell responses to antigenNadège Bercovici, Alice L Givan, Mary G Waugh, et al.
Case Reports in Oncology|April 24, 2019
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureNikhil Agrawal, Arjun Khunger, Pankit Vachhani, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2018
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survivalLawrence F Kuklinski, Shaofeng Yan, Zhongze Li, et al.
Clinical Immunology (Orlando, Fla.)|July 20, 2005
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patientsTodd S Crocenzi, Christopher P G Tretter, Thomas Schwaab, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancerLionel D Lewis, Andrew P Beelen, Bernard F Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)Raymond P Perez, Lionel D Lewis, Andrew P Beelen, et al.
Pageof 17